I'll research IDXX before writing the preview. Let me gather recent filings, transcripts, news, and price data.I have the key documents. Let me read the most recent earnings call (2026Q1), the Q1 earnings release, and the prior year Q2 for comparison. Let me also get news and price data.Now let me get the year-ago Q2 2025 call (the comp being lapped), recent news, and stock price action.Let me check for the most recent news and any analyst actions ahead of the print.I have what I need. Let me quickly compute a few precise stock and setup figures before writing.Now I have everything needed to write the preview.
Report date: Tuesday, August 4, 2026 (before market open) · 2026 Q2 Earnings Call, 8:30 a.m. ET Prepared as of 8/3/26. All figures company-reported unless noted.
This is the first quarter under new leadership (Mike Erickson as CEO; Jay Mazelsky moving to Executive Chair) and the quarter where IDEXX begins lapping its blowout year-ago comp — Q2 2025 was a record instrument-placement quarter that sent the stock up +27.5% on the print. Expectations are more grounded this time: management has already guided Q2 2026 to decelerating headline growth and an outright decline in instrument revenue, so the debate is less about the guided numbers and more about (a) whether U.S. clinic-visit "green shoots" are real, (b) the inVue Dx / FNA ramp, and (c) any strategic signaling from the incoming CEO ahead of the August Investor Day.
| Metric | Q2 2026 guide | Context |
|---|---|---|
| Reported revenue growth | 7.3% – 9.3% | includes ~60 bps FX tailwind |
| Organic revenue growth | 6.7% – 8.7% | includes a –50 bps drag from equivalent (fewer) days |
| CAG Dx recurring organic | 8.5% – 10.5% | the number that matters most |
| U.S. clinical visits | ~ –1.5% (in line w/ FY) | third+ straight quarter of –1% to –2% |
| Reported operating margin | 33.9% – 34.3% | +10–50 bps comparable; seasonally the peak-margin quarter |
| CAG instrument revenue | expected to DECLINE | lapping the huge 2025 inVue placements + regional/mix pressure |
Key nuance: the guided deceleration is optically driven by two known items — the fewer-days drag and the instrument-revenue decline against a monster comp — not by a change in the underlying recurring-revenue trajectory. CAG Dx recurring is still guided to 8.5–10.5% organic.
Year-ago comp to beat (Q2 2025): revenue +11% reported / +9% organic, CAG Dx recurring +7.4% organic, EPS $3.63, and a record 6,070 premium instrument placements including ~2,388 inVue Dx. That instrument record is exactly why 2026 instrument revenue is set to shrink year-over-year.
Q1 2026 was strong enough that IDEXX raised full-year guidance: - Revenue: $4,675M – $4,760M (8.6–10.6% reported; 7.7–9.7% organic) — up ~$42M / +70 bps organic at midpoint - CAG Dx recurring organic: 8.7–10.7% - EPS: $14.45 – $14.90 (11–15% comparable growth) - Operating margin: 32.1–32.5% (50–90 bps comparable expansion) - FY U.S. clinical visits nudged to –1.5% (a point better than the initial guide)
Q1 itself: revenue +11% organic ($1,141M), CAG Dx recurring +11% organic, EPS $3.47 (+15% comparable), gross margin 63.4% (+90 bps), and a striking ~1,100 bps premium of IDEXX's U.S. CAG Dx recurring growth over clinical visits. Watch whether Q2 confirms that raise or forces a rare mid-year trim.
1) U.S. clinic-visit trajectory & the "green shoots." Visits have run –1% to –2% for several quarters. The bull case rests on the aging pandemic-era pet cohort (5+ years) now driving positive growth in that age band, with non-well visits improving while wellness visits still decline (~ –3% in Q1). Investors will parse whether Q2 visits held at/better than –1.5% and whether diagnostic frequency/utilization per visit kept expanding.
2) inVue Dx placements & the FNA ramp. IDEXX reiterated a 5,500 full-year 2026 placement target (Q1 did 1,100, characterized as "choppy" quarter-to-quarter). Because Q2 2025 was the inVue launch-fueled record, instrument revenue will decline y/y — expected and messaged, but headline-ugly. The more important tell is FNA (fine-needle aspirate / "lumps and bumps"), which broadens from a controlled launch toward an unconstrained/full ramp in H2. FNA is central to hitting the $3,500–$5,500 recurring revenue-per-box band and to the multi-year ~20,000-unit inVue opportunity. Look for confirmation that per-box economics are tracking and that H2 ramp is on schedule.
3) IDEXX Cancer Dx. Now 7,500+ ordering practices, ~70% of North American tests run within a panel, ~20% of Cancer Dx customers are non-primary lab accounts (i.e., competitive lab pulls). The international launch (Europe, Australia) began in Q1; a mast-cell-tumor test is due later in 2026 and a third test by year-end. This is the key Reference Lab differentiator — watch for adoption metrics and international traction.
4) Margins & mix. Q2 is seasonally the high-margin quarter (guide 33.9–34.3%). Gross margin has been expanding on recurring-revenue leverage and productivity, but opex is rising on commercial expansion (four international + modest U.S. field-force additions), R&D, and "timing of project spend" flagged for Q2. Also lapping messy prior-year items (a 2025 litigation accrual; a Q1'26 $5M equity-investment loss). Watch clean comparable margin expansion.
5) International. International CAG Dx recurring grew +12% organic in Q1 — a decade-long double-digit streak driven by commercial density, localized products (ProCyte One), reference-lab buildout and VetConnect Plus. Continued double-digit international growth is the offset to soft U.S. visits and a core part of the durability thesis.
IDEXX has round-tripped its 2025 rally. After popping ~+27.5% on the Q2'25 print and running to a high near $766 (late Nov 2025), it closed $567.88 on 8/3/26 — ~26% off the 52-week high and down ~15% YTD 2026. The earnings-reaction pattern has cooled sharply:
| 1-day reaction | |
|---|---|
| Q2 2025 | +27.5% |
| Q3 2025 | +14.8% |
| Q4 2025 | –4.6% |
| Q1 2026 | ~flat |
The fade from euphoric beats-and-raises to muted/negative reactions tells you the bar has reset and multiple compression has done real damage despite still-strong fundamentals. With the stock roughly flat since the Q1 print and hovering near the lower end of its 12-month range, the risk/reward hinges on visit trends stabilizing and the new CEO reinforcing (not resetting) the growth algorithm.
Note: I was unable to retrieve fresh sell-side estimate revisions or pre-print news headlines for the days immediately ahead of the report, so consensus-vs-guide positioning above is framed against management's own guidance rather than a specific Street number.